Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer
NCT ID: NCT04945200
Last Updated: 2021-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-01-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2.18 years ≤ age ≤ 80 years
3.Histologically documented non-small cell lung cancer
4.NSCLC with resection option for potential cure.This may include clinical stage IB, II and IIIA.
5.Subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy according to disease evaluation.
6.Measurable disease by RECIST v1.1
7.Tumor tissue sample and/or alveolar lavage fluid must be available for biomarker evaluation before operation.
Exclusion Criteria
2. Administration of chemotherapy, device therapy or any other cancer therapy in 4 weeks before the study drug administration.
3. Subjects are excluded if they have an active, known or suspected autoimmune disease requiring systemic treatment (e.g.corticosteroids or other immunosuppressive medications) in 2 years before the study drug administration. substitution therapy ( e.g. thyroxine, insulin) are permitted.
4. Subjects with active concurrent malignancies are excluded i.e. cancers other than NSCLC.
5. History of allergy to study drug components
6. Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results.
7. Any other conditions that, in the Investigator's opinion, unfit to attend this study.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pingli Wang, M.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-1003
Identifier Type: -
Identifier Source: org_study_id